Keytruda (Pembrolizumab) Shows Promise for Advanced Merkel Cell Carcinoma
By Stacy SimonResults of a small clinical trial show that more than half the patients with Merkel cell carcinoma, a rare but aggressive type of skin cancer, improved when they took the immunotherapy drug Keytruda (pembrolizumab). And the improvement appears to be lasting longer than would be expected with standard treatment. This is a significant finding because there are currently no drugs that have been approved by the US Food and Drug Administration (FDA) to treat Merkel cell carcinoma. Researchers studying Keytruda and other drugs are trying to provide more treatment options for people with this type of skin cancer.While skin cancer is by far the most common type of cancer in the United States, Merkel cell carcinoma is not common. It’s thought that about 1,500 cases of Merkel cell carcinoma are diagnosed in the United States each year. It tends to spread quickly and can be hard to treat. While it often responds to chemotherapy, the improvement usually lasts only about 3 months.Researchers from cancer research centers across the US studied 25 people who took part in the clinical trial. All had Merkel cell carcinoma that had spread, and none had received chemotherapy. They were all given Keytruda. Fourteen of them (56%) improved, including 4 who had a complete response, meaning all signs of their cancer disappeared. After 6 months, 12 of the 14 were still doing well.The study was presented April 19 at the annual meeting of the American Association for Cancer Research ...
Publication date: 15 February 2021Source: Journal of Hazardous Materials, Volume 404, Part BAuthor(s): Yanhua Liu, Yang Li, Shanshan Dong, Lu Han, Ruixin Guo, Yourong Fu, Shenghu Zhang, Jianqiu Chen
We describe the most highly recommended generic and disease-specific PRO tools in SCD and discuss the challenges of incorporating them in clinical practice. EXPERT OPINION: PRO measures are essential to incorporate into SCD clinical trials either as primary or secondary outcomes. The use of PRO measures in SCD facilitates a patient-centered approach, which is likely to lead to improved outcomes. Significant challenges remain in adapting PRO tools to routine clinical use and in developing countries. PMID: 33034214 [PubMed - as supplied by publisher]
Authors: Musio F Abstract INTRODUCTION: Anemia has and will continue to be a central theme in medicine particularly as clinicians are treating a burgeoning population of complex multi-organ system processes. As a result of multiple randomized controlled trials (RCTs), meta-analyses, and societal recommendations overly restrictive paradigms and under-administration of erythropoiesis stimulating agents (ESAs) have likely been followed by clinicians among all specialties. AREAS COVERED: A review of anemia in the context of chronic kidney disease, hematologic malignancies and cancer is presented with focus on the e...
Publication date: January 2021Source: Urology Case Reports, Volume 34Author(s): Nina Al-Saadi, Safa Al-Musawi, Yousuf Khan, Daben Dawam
Publication date: Available online 10 October 2020Source: European UrologyAuthor(s): Stanley Weng, Renzo G. DiNatale, Andrew Silagy, Roy Mano, Kyrollis Attalla, Mahyar Kashani, Kate Weiss, Nicole E. Benfante, Andrew G. Winer, Jonathan A. Coleman, Victor E. Reuter, Paul Russo, Ed Reznik, Satish K. Tickoo, A. Ari Hakimi
CONCLUSIONS: Xyloglucan/gelose plus ORS was effective and safe in treating acute diarrhea in children. PMID: 33028102 [PubMed - as supplied by publisher]
Publication date: Available online 10 October 2020Source: European Journal of Surgical OncologyAuthor(s): Tetsutaro Miyoshi, Satoshi Yamaguchi, Hiroshi Fujimoto, Shigeru Yoshioka, Masayuki Shiobara, Kazuo Wakatsuki, Kosuke Suda, Kotaro Miyazawa, Toshiaki Aida, Yoshihiro Watanabe, Masayuki Ohtsuka
Currently in fellowship doing bread/butter procedures (MBB, epidurals, PNB, few SCS/PNS trials, etc.) and just interviewed at a private practice spot where they do a lot of procedures that I will have not done any training in prior to graduating (e.g. IT pump, SI fusion, Vertiflex, Kypho, MILD, Discectomy, lots of SCS/PNS trials etc) and significant amount of "OR pain procedures" at a very busy practice seeing 30-40 pts/day - how many of you are commonly performing these procedures and are... private practice concern
Publication date: Available online 10 October 2020Source: Respiratory Medicine Case ReportsAuthor(s): Vipul Patel, Tilottama Majumdar, Isha Samreen, Harpreet Grewal, Thomas Kaleekal
Authors: Matti B, Zargar-Shoshtari K Abstract Prostate cancer represents a significant health burden worldwide. The cancer incidence had substantially increased since the introduction of prostate specific antigen (PSA) in cancer screening. This had led to considerable debates among health professionals and epidemiologists, since PSA as a screening tool seemed to be far from perfect. In New Zealand, the controversy was quite prominent in the last three decades, with some advocating the benefits of screening, while others concerned regarding the risk of harms. With the absence of an organised screening programme and ...
More News: Cancer | Cancer & Oncology | Carcinoma | Cardiology | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Constipation | Cough | Eyes | Food and Drug Administration (FDA) | Health | Health Management | Heart | Hepatocellular Carcinoma | Hormones | Immunotherapy | Itchiness | Liver | Liver Cancer | Lung Cancer | Melanoma | Merkel Cell Carcinoma | Pain | Skin | Skin Cancer | Study | University of Washington | Urology & Nephrology